Actuate Therapeutics, Inc. (ACTU)
NASDAQ:ACTU
ACTU Stock Chart & Stats
$2.31
-$0.11(-1.36%)
At close: 4:00 PM EST
$2.31
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$1.58 - $9.22
Previous CloseN/A
Volume10.16K
Average Volume (3M)157.58K
Market Cap
$49.53M
Enterprise Value$41.32M
Total Cash (Recent Filing)$8.13M
Total Debt (Recent Filing)$404.99K
Price to Earnings (P/E)―
Beta1.45
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding23,925,852
10 Day Avg. Volume215,363
30 Day Avg. Volume157,584
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)16.24
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.92
Forecast
1Y Price Target
$10.67Price Target Upside361.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.8
Revenue Forecast (FY)N/A
Actuate Therapeutics, Inc. News
ACTU FAQ
What was Actuate Therapeutics, Inc.’s price range in the past 12 months?
Actuate Therapeutics, Inc. lowest stock price was $1.58 and its highest was $9.22 in the past 12 months.
What is Actuate Therapeutics, Inc.’s market cap?
Actuate Therapeutics, Inc.’s market cap is $49.53M.
When is Actuate Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Actuate Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Actuate Therapeutics, Inc. overvalued?
According to Wall Street analysts Actuate Therapeutics, Inc.’s price is currently Undervalued.
Does Actuate Therapeutics, Inc. pay dividends?
Actuate Therapeutics, Inc. does not currently pay dividends.
What is Actuate Therapeutics, Inc.’s EPS estimate?
Actuate Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actuate Therapeutics, Inc. have?
Actuate Therapeutics, Inc. has 23,925,852 shares outstanding.
What happened to Actuate Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Actuate Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACTU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actuate Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (361.76% Upside)
$10.67 (361.76% Upside)
Blogger Sentiment
Bullish
ACTU Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.36%
12-Months-Change
Fundamentals
Return on Equity
-430.93%
Trailing 12-Months
Asset Growth
98.78%
Trailing 12-Months
Company Description
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
ACTU Stock 12 Month Forecast
Average Price Target
$10.67
▲(361.76% Upside)
Technical Analysis
Agenus
―
Black Diamond Therapeutics
―
Nkarta
―
C4 Therapeutics
―
Kyverna Therapeutics, Inc.
―